natgillin/translations-raw huggingface dataset:
GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) powder and solvent for solution for injection.
GONAL-f 450 i.e./ 0,75 ml (33 mikrogramov/0,75 ml) prašek in vehikel za raztopino za injiciranje
GONAL-f 450 IU/0.75 ML (33 MICROGRAMS/0.75 ML), VIAL LABEL
GONAL-F 450 I.E./0,75 ML (33 MIKROGRAMOV/0,75 ML) NALEPKA NA VIALI
gonal-f 75 iu
gonal-f 75 i.e.
GONAL-f 75 IU (5.5 micrograms) powder and solvent for solution for injection.
GONAL-f 75 i.e. (5,5 mikrograma) prašek in vehikel za raztopino za injiciranje
GONAL-f 75 IU (5.5 MICROGRAMS) VIAL LABEL
GONAL-F 75 I.E. (5,5 MIKROGRAMA) NALEPKA NA VIALI
GONAL-f 900 IU/1.5 mL
GONAL-f 900 i.e./1,5 ml
GONAL-f 900 IU/1.5 ML (66 MICROGRAMS/1.5 ML) PEN, PEN LABEL
GONAL-f 900 I.E./1,5 ML (66 MIKROGRAMOV/1,5 ML), NAPOLNJEN INJEKCIJSKI PERESNIK, NALEPKA NA INJEKCIJSKEM PERESNIKU
GONAL-f 900 IU/1.5 mL (66 micrograms/1.5 mL) solution for injection in pre-filled pen.
GONAL-f 900 i.e./1,5 ml (66 mikrogramov/1,5 ml) raztopina za injiciranje v napolnjenem injekcijskem peresniku
GONAL-f contains a medicine called “follitropin alfa”.
GONAL-f vsebuje zdravilno učinkovino ki se imenuje "folitropin alfa".
GONAL-f contains a medicine called “follitropin alfa”.
Zdravilo GONAL-f vsebuje zdravilno učinkovino, ki se imenuje "folitropin alfa".
GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency.
Zdravilo GONAL-f se priporoča skupaj z luteinizirajočim hormonom (LH) za spodbujanje razvoja foliklov pri ženskah s hudim pomanjkanjem LH in FSH.
GONAL-f is administered for 7 days.
7 dni daje 150 do 225 i.e. zdravila GONAL-f.
GONAL-f is expected to have no or negligible influence on the ability to drive and use machines.
Pričakuje se, da zdravilo GONAL-f nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
GONAL-f is given to stimulate the ovaries to produce more than one egg at a time; adult women with severe deficiency (very low levels) of luteinising hormone (LH) and follicle stimulating hormone (FSH).
Zdravilo GONAL-f se daje za spodbujanje jajčnikov k izdelavi več kot enega jajčeca naenkrat; pri odraslih ženskah s hudim pomanjkanjem (zelo nizkimi ravnmi) luteinizirajočega hormona (LH) in folikle stimulirajočega hormona (FSH).
GONAL-f is given together with a medicine containing LH to stimulate the eggs to mature in the ovaries; adult men who have hypogonadotrophic hypogonadism (a rare hormone deficiency disease).
Zdravilo GONAL-f se daje skupaj z zdravili, ki vsebujejo LH, kar spodbudi jajčeca, da dozorijo v jajčnikih; pri odraslih moških, ki imajo hipogonadotropni hipogonadizem (redko bolezen pomanjkanja hormona).
GONAL-f is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotropin (hCG) therapy.
Zdravilo GONAL-f je s sočasnim zdravljenjem s humanim horionskim gonadotropinom (hCG) indicirano za stimulacijo spermatogeneze pri moških, ki imajo prirojen ali pridobljen hipogonadotropni hipogonadizem.
GONAL-f is presented as a clear, colourless liquid for injection in a pre-filled pen.
Zdravilo GONAL-f je na voljo v obliki bistre, brezbarvne tekočine za injiciranje v napolnjenem injekcijskem peresniku.
GONAL-f may be given as a course of daily injections.
Zdravilo GONAL-f se lahko daje kot zaporedje dnevnih injekcij.
Gonarthrosis
Pogosti
Gonazon contains azagly-nafarelin, which is an analogue of a natural hormone called gonadotrophin- releasing hormone (GnRH).
Zdravilo Gonazon vsebuje azagli-nafarelin, ki je analog naravnega hormona, imenovanega gonadotropin sproščajoči hormon (GnRH).
Gonzagagasse 16/16 1010 Vienna Austria
1010 Dunaj Avstrija
Good injection sites are the top of the thigh and around the tummy (abdomen) but away from the navel.
Primerna mesta za injiciranje so na vrhu stegna in okoli trebuha (abdomna), vendar ne blizu popka.
Good management and hygiene practices should be followed to reduce the risk of re-infection.
Za zmanjšanje tveganja za ponovno okužbo bi morali uvesti dobre prakse upravljanja in higienske prakse.
Good management and hygiene practices should be introduced in order to reduce the risk of re- infection.
Za zmanjšanje tveganja ponovne okužbe uvedite dobre prakse upravljanja in dobre higienske prakse.
Good management and hygiene practices should be introduced in order to reduce the risk of re- infection.
Za zmanjšanje tveganja za ponovno okužbo bi morali uvesti dobre prakse upravljanja in higienske prakse.
Good management and hygiene practices should be introduced to reduce the risk of re-infection.
Za zmanjšanje tveganja ponovne okužbe bi morali uvesti dobre prakse upravljanja in higienske prakse.
Good management and hygiene practices should be introduced to reduce the risk of re-infection.
Za zmanjšanje tveganja ponovne okužbe uvedite dobre prakse upravljanja in dobre higienske prakse.
Good places for the injection are the upper thigh or around the belly (abdomen) at least 5 cm away from the navel (belly button)
Primerna mesta za injiciranje zdravila so zgornji del stegna ali trebuh (abdomen), in sicer najmanj 5 cm stran od popka.
Good sites are the top of the thigh and around the tummy (abdomen) but away from the navel.
Primerna mesta za injiciranje so na vrhu stegna in okoli trebuha (abdomna), vendar ne blizu popka.
Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures, such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting.
V skladu z dobro veterinarsko prakso se antiemetike uporablja v povezavi z ostalimi veterinarskimi in podpornimi terapijami, kot je dieta in tekočinska terapija, hkrati pa se zdravi osnovne vzroke bruhanja.
Good wound care measures include:
Ukrepi pravilne oskrbe ran vključujejo:
gout
protin,
gout
putika
gout
putika,
gout (a condition of painful, swollen joints caused by uric acid crystals) worsening of food allergies.
protin (boleči, otekli sklepi, kar povzročijo kristali sečne kisline) poslabšanje alergij na hrano.
gout (a condition of painful, swollen joints caused by uric acid crystals) worsening of food allergies.
protin (boleči, otekli sklepi, kar povzročijo kristali sečne kisline), poslabšanje alergij na hrano.
gout abnormal blood tests (decreased glucose, elevated potassium, abnormal liver function, elevated type of white blood cell i.e. eosinophilia)
protin nenormalni izvidi krvnih preiskav (zmanjšanje glukoze, zvišanje kalija, nenormalno delovanje jeter, povečana raven vrste belih krvnih celic, tj. eozinofilija).
Gout flare prophylaxis with colchicine or a nonsteroidal anti-inflammatory drug (NSAID) is recommended for at least 5 months when starting therapy (see section 4.4).
Na začetku zdravljenja je vsaj 5 mesecev priporočljiva profilaksa napadov protina s kolhicinom ali nesteroidnim protivnetnim zdravilom (NSAID – Non-Steroidal Anti-Inflammatory Drug) (glejte poglavje 4.4).
Gout flares
Napadi protina
Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits (see section 4.8 and 5.1).
Ob začetku zdravljenja se lahko pojavi izbruh protina zaradi spremenjene ravni sečne kisline v serumu, kar povzroči mobilizacijo urata iz depozitov v tkivih (glejte poglavje 4.8 in 5.1).
gout medicines (allopurinol)
zdravil proti protinu (alopurinola)
gout medicines (allopurinol),
zdravil proti protinu (alopurinol),
gout medicines (allopurinol),
zdravil proti protinu (alopurinola),
gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase
protin, anoreksija, zmanjšan tek, zmanjšana telesna masa, zvečana telesna masa, hiperglikemija, odpornost na insulin, znižana koncentracija lipoproteinov visoke gostote, zvečan tek, polidipsija, povišana koncentracija laktat-dehidrogenaze v krvi
Gout.
protin,
Gout.
Protin.
Gout/Gouty Arthritis
protin/protinski artritis
Gout: The recommended dose in patients with mild hepatic impairment is 80 mg.
Protin: Priporočeni odmerek pri bolnikih z blago okvaro jeter je 80 mg.
Gouty arthritis is caused by the deposition of a chemical called urate crystals in the body.
Urični artritis povzročajo snovi, imenovane uratni kristali, ki se odlagajo v telesu.
gp inducer]
P-gp]
gp inhibition
CYP3A4/P-gp s
gp inhibition.
Zavrtje
GPIIb/IIIa inhibitors were permitted for bailout use only and were used in 2.9% of patients.
Zaviralci GPIIb/IIIa so bili dovoljeni le za reševalno uporabo in so bili uporabljeni pri 2,9 % bolnikov.
Grab pre-filled syringe safety guard to remove pre-filled syringe from tray.
Napolnjeno injekcijsko brizgo vzemite iz podloge tako, da jo primete za njen varnostni ščitnik.
Grab the loose edge at either corner and peel off the second piece of the liner.
Primite kot odpuščenega roba in odlepite drugi del folije.
Grade (CTC-AE) (a)
Stopnja neželenega dogodka (CTC-AE)(a)
Grade (CTC-AE)*
Stopnja (CTC- AE)
Grade (CTC-AE)*
Stopnja (CTC-AE)
Grade 1
Stopnja 4
Grade 1
topnja 1
Grade 1 (asymptomatic; loss of deep tendon reflexes or paraesthesia) with no pain or loss of function
Stopnja 1 (asimptomatična; izguba refleksa globoke tetive ali parestezija) brez bolečine ali izguba funkcije
Grade 1 (asymptomatic; loss of deep tendon reflexes or paresthesia) with no pain or loss of function
Stopnja 1 (asimptomatična; izguba refleksa globoke tetive ali parestezija) brez bolečine ali izguba funkcije
Grade 1 (painless ulcers, erythema, or mild soreness)
Stopnja 1 (neboleče razjede, eritem ali blaga bolečnost)
Grade 1 and Grade 2 diabetes mellitus and Grade 4 diabetic ketoacidosis were each reported in 0.2% (1/448) of patients.
O diabetesu stopnje 1 in stopnje 2 ter diabetični ketoacidozi stopnje 4 so poročali pri 0,2 % (1/448) bolnikov.
Grade 1 hand- foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient’s normal activities.
Sindrom 1. stopnje se kaže kot otrplost, disestezija ali parestezija, mravljinčenje, neboleče otekanje ali rdečina rok in nog ali obojih okončin oziroma kot neugodje, ki ne vpliva na bolnikove normalne dejavnosti.
Grade 1 hand-foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient’s normal activities.
Sindrom 1. stopnje se kaže kot otrplost, disestezija ali parestezija, mravljinčenje, neboleče otekanje ali rdečina rok in nog ali obojih okončin oziroma kot neugodje, ki ne vpliva na bolnikove normalne dejavnosti.
Grade 1 RPED
RPED 1. stopnje
Grade 1-2
Stopnja 1–2
Grade 1-2 (mild to moderate): Once the patient’s condition is stable, the infusion should be resumed at no more than half the rate at which the IRR occurred.
Reakcija stopnje 1-2 (blaga do zmerna): Ko se bolnikovo stanje stabilizira, lahko ponovno začnete infundiranje s hitrostjo, ki ne presega polovične vrednosti hitrosti infundiranja, pri kateri je do infuzijske reakcije prišlo.
Grade 1-2 (mild to moderate): The infusion rate must be reduced and symptoms treated.
1. do 2. stopnja (blage do zmerne): Hitrost infundiranja je treba zmanjšati in zdraviti simptome.
Grade 1: continue slow infusion under close supervision
1. stopnja: nadaljujte s počasnim infundiranjem pod skrbnim nadzorom
Grade 2
stopnjo)
Grade 2
topnja 2
Grade 2
topnja stopnja
Grade 2 (<75, ≥50x109/l)
Stopnja 2 (<75, ≥50x109/l)
Grade 2 (erythema, desquamation, or swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations less than 2 cm in diameter)
Stopnja 2 (eritem, deskvamacija ali otekanje, ki ovira, a ne preprečuje vsakodnevnih telesnih dejavnosti; majhni mehurji ali razjede s premerom, manjšim od 2 cm)
Grade 2 (intolerable) or Grade 3
Stopnja 2 (neprenosljivo) ali stopnja 3
Grade 2 (intolerable) or Grade 3/4
Stopnja 2 (neznosni) ali stopnja 3/4
Grade 2 (prolonged c or intolerable) or
topnja 2 (traja dalj časa c ali ga bolnik ne prenaša) ali
Grade 2 (≥1x109/l)
Stopnja 2 (≥1x109/l)
Grade 2 ( 1.5 to ≤ 3  the ULN)
2. stopnja ( 1,5 do ≤ 3  ZNM)
Grade 2 ( 2.5 to ≤ 5  the ULN)
2. stopnja ( 2,5 do ≤ 5  ZNM)
Grade 2 and Grade 3 adrenal insufficiency each occurred in 1.1% (5/448), and Grade 4 adrenal insufficiency occurred in 0.2% (1/448) of patients.
Tako o insuficienci nadledvičnih žlez stopnje 2 kot stopnje 3 so poročali pri 1,1 % (5/448) bolnikov, o insuficienci nadledvičnih žlez stopnje 4 pa pri 0,2 % (1/448) bolnikov.
Grade 2 and Grade 3 cases were reported in 19.2% (86/448) and 7.4% (33/448) of patients, respectively.
O primerih stopnje 2 so poročali pri 19,2 % (86/448) bolnikov, o primerih stopnje 3 pa pri 7,4 % (33/448) bolnikov.
Grade 2 and Grade 3 hypophysitis occurred in 6.0% (27/448) and 1.8% (8/448) of patients, respectively.
O vnetju hipofize stopnje 2 so poročali pri 6,0 % (27/448) bolnikov, o vnetju hipofize stopnje 3 pa pri 1,8 % (8/448) bolnikov.
Grade 2 and Grade 3 thyroid disorders were reported in 13.4% (60/448) and 1.6% (7/448) of patients, respectively.
O boleznih ščitnice stopnje 2 so poročali pri 13,4 % (60/448) bolnikov, o boleznih ščitnice stopnje 3 pa pri 1,6 % (7/448) bolnikov.
Grade 2 diarrhoea or colitis Withhold dose(s) until symptoms resolve and management with corticosteroids, if needed, is complete
Driska ali kolitis stopnje 2 Aplikacijo odmerka (odmerkov) zadržite dokler simptomi ne izzvenijo in zdravljenje s kortikosteroidi, če je bilo potrebno, ni končano.
Grade 2 hand- foot syndrome is painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient’s activities of daily living.
Za sindrom 2. stopnje so značilni boleča rdečina in otekanje rok ali nog ali obojih okončin oziroma neugodje, ki že vpliva na bolnikove vsakodnevne dejavnosti.
Grade 2 hand-foot syndrome is painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient’s activities of daily living.
Za sindrom 2. stopnje so značilni boleča rdečina in otekanje rok ali nog ali obojih okončin oziroma neugodje, ki že vpliva na bolnikove vsakodnevne dejavnosti.
Grade 2 or 3 creatinine elevation Withhold dose(s) until creatinine returns to baseline and management with corticosteroids is complete
Aplikacijo odmerka (odmerkov) zadržite dokler se vrednost kreatinina ne povrne do izhodiščne vrednosti in zdravljenje s kortikosteroidi ni končano.
Grade 2 or 3 cutaneous toxicity
kožna toksičnost 2. ali 3. stopnje
Grade 2 pancreatitis and/or asymptomatic elevation of lipase/amylase
Pankreatitis 2. stopnje in/ali asimptomatsko zvišanje ravni lipaze/amilaze
Grade 2 peripheral motor neuropathy
Stopnja 2 periferna motorična nevropatija
Grade 2 pneumonitis Withhold dose(s) until symptoms resolve, radiographic abnormalities improve, and management with corticosteroids is complete
Pnevmonitis stopnje 2 Aplikacijo odmerka (odmerkov) zadržite dokler simptomi ne izzvenijo, radiografsko ugotovljene nepravilnosti ne izboljšajo in zdravljenje s kortikosteroidi ni končano.
Grade 2 pneumonitis Withhold Nivolumab BMS until
Pnevmonitis stopnje 2 Aplikacijo zdravila Nivolumab BMS
Grade 2 ‘blood bilirubin increased’ was reported in one patient (0.3%) receiving 12 weeks of treatment.
O 'zvečanju koncentracije bilirubina v krvi' stopnje 2 so poročali pri enem bolniku (0,3%; skupina, ki je zdravljenje prejemala 12 tednov).
Grade 2  5 days or Grade  3 any duration1
Mukozitis in zaprtost stopnje 2, ki traja 5 dni ali stopnje 3, ne glede na trajanje1
Grade 2, 3 Bradycardiac,d
bradikardija stopnje 2, 3c, d
Grade 2, 3 or 4 ALT or AST elevation with concurrent Grade 2, 3 or 4 total bilirubin elevation (in the absence of cholestasis or haemolysis)
povečanje vrednosti ALT ali AST stopnje 2, 3 ali 4 ob sočasnem povečanju vrednosti skupnega bilirubina stopnje 2, 3 ali 4 (v odsotnosti holestaze ali hemolize)
Grade 2, Grade 3, and Grade 4 cases were reported in 1.1% (5/448), 0.9% (4/448), and 0.7% (3/448) of patients, respectively.
O primerih stopnje 2 so poročali pri 1,1 % (5/448) bolnikov, o primerih stopnje 3 pri 0,9 % (4/448) bolnikov, o primerih stopnje 4 pa pri 0,7 % (3/448) bolnikov.
Grade 2, Grade 3, and Grade 4 cases were reported in 13.2% (59/448), 15.4% (69/448), and 0.4% (2/448) of patients, respectively.
O primerih stopnje 2 so poročali pri 13,2 % (59/448) bolnikov, o primerih stopnje 3 pri 15,4 % (69/448) bolnikov, o primerih stopnje 4 pa pri 0,4 % (2/448) bolnikov.
Grade 2, Grade 3, and Grade 4 cases were reported in 4.5% (20/448), 1.1% (5/448), and 0.2% (1/448) of patients, respectively.
O primerih stopnje 2 so poročali pri 4,5 % (20/448) bolnikov, o primerih stopnje 3 pri 1,1 % (5/448) bolnikov, o primerih stopnje 4 pa pri 0,2 % (1/448) bolnikov.
Grade 2, Grade 3, and Grade 4 cases were reported in 6.3% (28/448), 15.0% (67/448), and 1.8% (8/448) of patients, respectively.
O primerih stopnje 2 so poročali pri 6,3 % (28/448) bolnikov, o primerih stopnje 3 pri 15,0 % (67/448) bolnikov, o primerih stopnje 4 pa pri 1,8 % (8/448) bolnikov.
Grade 2-4 creatine kinase laboratory abnormalities were observed in subjects treated with ISENTRESS.
Pri osebah, ki so se zdravile z zdravilom ISENTRESS, so poročali o nenormalnih laboratorijskih vrednostih kreatin-kinaze (2.-4. stopnje).
Grade 2: continue slow infusion and immediately administer treatment for symptoms
2. stopnja: nadaljujte s počasnim infundiranjem in takoj dajte zdravilo za simptome
Grade 2b,c
Stopnja 2b,c
Grade 3
2. stopnja
Grade 3
Podskupina bolnic
Grade 3
topnja 3
Grade 3 & 4 (<50x109/l)
Stopnja 3 in 4 (<50x109/l)
Grade 3 & 4 n (%)
3. in 4. stopnja n (%)
Grade 3 (%)
Stopnja 3 (%)
Grade 3 (%)
topnja 3 (%)
Grade 3 (<1, ≥0.5x109/l)
Stopnja 3 (<1, ≥0,5x109/l)
Grade 3 (> 5.0 to 20.0 times ULN) elevations occurred in <4% of patients treated with GIOTRIF (see section 4.4).
3. stopnje (> 5,0- do 20,0-kratna ULN) se je pojavilo pri < 4% bolnikov, zdravljenih z zdravilom GIOTRIF (glejte poglavje 4.4).
Grade 3 (blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing)
Stopnja 3 (mehurji, razjede ali otekanje, ki ovirajo hojo ali
Grade 3 (despite optimal antihypertensive therapy)
topnja 3 (kljub optimalnemu antihipertenzivnemu zdravljenju)
Grade 3 (despite optimal antihypertensive therapy)
topnja 3 (kljub optimalni antihipertenzivni terapiji)
Grade 3 (first occurrence) Withhold dose(s)
Stopnje 3 (prvi pojav) Aplikacijo odmerka (odmerkov) zadržite.
Grade 3 (severe)
Stopnja 3 (resna)
Grade 3 (severe): If the intensity of the IRR decreases to Grade 2 or lower, restarting of the infusion may be considered at no more than half the rate at which the reaction occurred.
Reakcija stopnje 3 (huda): Če se intenzivnost infuzijske reakcije zmanjša na stopnjo 2 ali manj, lahko razmislite o ponovnem začetku infundiranja s hitrostjo, ki ne presega polovične vrednosti hitrosti infundiranja, pri kateri je do infuzijske reakcije prišlo.
Grade 3 (severe): Infusion must be temporarily stopped and symptoms treated.
3. stopnja (hude): Infundiranje je treba začasno ustaviti in zdraviti simptome.
Grade 3 ( 3 to ≤ 10  the ULN)
3. stopnja ( 3 do ≤ 10  ZNM)
Grade 3 ( 5 to ≤ 20  the ULN)
3. stopnja ( 5 do ≤ 20  ZNM)
Grade 3 -
Toksičnost stopnje
Grade 3 - 4 toxicit y (%)
3 - 4 (%)
Grade 3 - 4 toxicity (%)
3 – 4 (%)
Grade 3 - 4 toxicity (%)
Toksičnos t stopnje 3 – 4 (%)
Grade 3 - 4 toxicity (%)
Toksičnos t stopnje 3 –4 (%)
Grade 3 - 4 toxicity (%)
Toksičnost stopnje 3 – 4 (%)
Grade 3 - 4 toxicity (%)
Toksičnost vseh stopenj (%)
Grade 3 and 4 cases were reported in 0.5% (8/1728) and
O primerih stopnje 3 so poročali pri 0,5 % (8/1.728) bolnikov, o primerih stopnje 4 pa pri
Grade 3 and 4 cases were reported in 0.8% (14/1728) and <0.1% (1/1728) of patients respectively.
O primerih stopnje 3 so poročali pri 0,8 % (14/1.728) bolnikov, o primerih stopnje 4 pa pri < 0,1 % bolnikov (1/1.728).
Grade 3 and 4 cases were reported in 1.4% (25/1728) and 0.3% (6/1728) of patients, respectively.
O primerih stopnje 3 so poročali pri 1,4 % (25/1.728) bolnikov, o primerih stopnje 4 pa pri 0,3 % (6/1.728) bolnikov.
Grade 3 and 4: stop infusion immediately, treat symptoms vigorously and contraindicate further use of cetuximab
3. in 4. stopnja: takoj ustavite infundiranje, aktivno zdravite simptome in kontraindicirajte nadaljnjo uporabo cetuksimaba
Grade 3 cases were reported in 1.6% (27/1728) of patients.
O primerih stopnje 3 so poročali pri 1,6 % (27/1.728) bolnikov.
Grade 3 compromised wound healing was reported in 2 patients (0.3%) treated with the ZALTRAP/FOLFIRI regimen and in none of the patients treated with the placebo/FOLFIRI regimen.
Slabše celjenje ran 3. stopnje se je pojavilo pri 2 (0,3 %) prejemnikih sheme ZALTRAP/FOLFIRI, med prejemniki sheme placebo/FOLFIRI pa se ni pojavilo.
Grade 3 diarrhoea
driska 3. stopnje
Grade 3 diarrhoea or colitis
Driska ali kolitis stopnje 3
Grade 3 fatigue (dose limiting toxicity) and Grade 3 hypertension were each observed in 1 of 3 patients dosed at 2000 mg and 1000 mg daily, respectively.
Utrujenost 3. stopnje (toksični učinek, ki omejuje odmerek) oziroma hipertenzijo 3. stopnje so ugotovili pri 1 od 3 bolnikov, ki so prejemali odmerek 2000 mg oziroma 1000 mg na dan.
Grade 3 GI fistula formation occurred in 2 patients treated with ZALTRAP (0.3%) and in 1 placebo-treated patient (0.2%).
Fistula na prebavilih 3. stopnje se je pojavila 2 prejemnikoma zdravila ZALTRAP (0,3 %) in 1 prejemniku placeba (0,2 %).
Grade 3 hypertension (requiring adjustment in existing anti-hypertensive therapy or treatment with more than one medicinal product) was reported in 1.5% of patients treated with the placebo/FOLFIRI regimen and 19.1% of patients treated with the ZALTRAP/FOLFIRI regimen.
Hipertenzija 3. stopnje (ki je zahtevala prilagoditev obstoječega antihipertenzivnega zdravljenja ali zdravljenje z več kot enim zdravilom) je bila opisana pri 1,5 % prejemnikov sheme placebo/FOLFIRI in pri 19,1 % prejemnikov sheme ZALTRAP/FOLFIRI.
Grade 3 mucositis
mukozitis 3. stopnje
Grade 3 n (%)
3. stopnja n (%)
Grade 3 n (%)
topnja 3 št. (%)
Grade 3 or 4 adrenal insufficiency
Insuficienca nadledvičnih žlez stopnje 3 ali 4
Grade 3 or 4 elevation in AST, ALT, or total bilirubin
Zvišanje vrednosti AST, ALT ali skupnega bilirubina stopnje 3 ali 4 Zvišanje vrednosti kreatinina stopnje 2 ali 3
Grade 3 or 4 elevations of triglycerides occurred more frequently in the tipranavir with ritonavir arm compared with the comparator arm.
Povečanje trigliceridov 3. ali 4. stopnje je bilo pri bolnikih, ki so prejemali tipranavir ob ritonavirju, pogostnejše kot v primerjalni skupini.
Grade 3 or 4 events were reported in 0.4% of patients.
4. stopnje so zabeležili pri 0,4 % bolnikov.
Grade 3 or 4 febrile neutropenia episodes were observed in 2.2% of lenalidomide-treated patients compared with 0.0% in patients on placebo).
Epizode febrilne nevtropenije 3. ali 4. stopnje so opazili pri 2,2 % bolnikov, ki so prejemali lenalidomid, v primerjavi z 0,0 % pri bolnikih, ki so prejemali placebo.
Grade 3 or 4 febrile neutropenia episodes were observed in 6.0% of lenalidomide-treated patients compared with 2.4% in patients on control arm.
Epizode febrilne nevtropenije 3. ali 4. stopnje so opazili pri 6,0 % bolnikov, zdravljenih z lenalidomidom, v primerjavi z 2,4 % pri bolnikih v kontrolni skupini.
Grade 3 or 4 infusion reactions are uncommon after the first week of therapy.
Reakcije zaradi infundiranja tretje in četrte stopnje se redko pojavijo v prvem tednu zdravljenja.
Grade 3 or 4 motor or sensory neuropathy
motorična ali senzorična nevropatija stopnje 3 ali 4
Grade 3 or 4 non-hematologic medicine related toxicity
V primeru pojava nehematološke toksičnosti 3. ali 4. stopnje v povezavi z uporabo zdravila
Grade 3 or 4 pneumonitis Permanently discontinue treatment
Pnevmonitis stopnje 3 ali 4 Zdravljenje trajno ukinite.
Grade 3 or 4 reactions occurred in 1.0 % of patients who received Pom + LD-Dex and in 1.3% of patients who received HD-Dex.
Reakcije 3. ali 4. stopnje so se pojavile pri 1,0 % bolnikov, ki so prejemali Pom + NO-deks, in pri 1,3 % bolnikov, ki so prejemali VO-deks.